DOCSLIB.ORG

Treatment for Superficial Thrombophlebitis of The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Treatment for Superficial Thrombophlebitis of The Treatment for superficial thrombophlebitis of the leg (Review) Di Nisio M, Wichers IM, Middeldorp S This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2012, Issue 3 http://www.thecochranelibrary.com Treatment for superficial thrombophlebitis of the leg (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 5 Figure1. ..................................... 7 Figure2. ..................................... 8 DISCUSSION ..................................... 11 AUTHORS’CONCLUSIONS . 12 ACKNOWLEDGEMENTS . 12 REFERENCES ..................................... 12 CHARACTERISTICSOFSTUDIES . 17 DATAANDANALYSES. 42 Analysis 1.1. Comparison 1 Fondaparinux versus placebo, Outcome 1 Pulmonary embolism. 51 Analysis 1.2. Comparison 1 Fondaparinux versus placebo, Outcome 2 Deep vein thrombosis. 51 Analysis 1.3. Comparison 1 Fondaparinux versus placebo, Outcome 3 Deep vein thrombosis and pulmonary embolism. 52 Analysis 1.4. Comparison 1 Fondaparinux versus placebo, Outcome 4 Extension of ST. 52 Analysis 1.5. Comparison 1 Fondaparinux versus placebo, Outcome 5 Recurrence of ST. 53 Analysis 1.6. Comparison 1 Fondaparinux versus placebo, Outcome 6 Mortality. 53 Analysis 1.7. Comparison 1 Fondaparinux versus placebo, Outcome 7 Major bleeding. 54 Analysis 1.8. Comparison 1 Fondaparinux versus placebo, Outcome 8 Clinically relevant non-major bleeding. 54 Analysis 1.9. Comparison 1 Fondaparinux versus placebo, Outcome 9 Minor bleeding. 55 Analysis 1.10. Comparison 1 Fondaparinux versus placebo, Outcome 10 Arterial thromboembolic complication. 55 Analysis 1.11. Comparison 1 Fondaparinux versus placebo, Outcome 11 Any adverse event. 56 Analysis 1.12. Comparison 1 Fondaparinux versus placebo, Outcome 12 Non-fatal serious adverse event. 56 Analysis 2.1. Comparison 2 Prophylactic LMWH versus placebo, Outcome 1 Venous thromboembolism end-of- treatment.................................... 57 Analysis 2.2. Comparison 2 Prophylactic LMWH versus placebo, Outcome 2 Venous thromboembolism 3-month follow up. ..................................... 57 Analysis 2.3. Comparison 2 Prophylactic LMWH versus placebo, Outcome 3 Extension and/or recurrence of ST. 58 Analysis 2.4. Comparison 2 Prophylactic LMWH versus placebo, Outcome 4 Major bleeding. 58 Analysis 2.5. Comparison 2 Prophylactic LMWH versus placebo, Outcome 5 Heparin-induced thrombocytopenia. 59 Analysis 3.1. Comparison 3 Therapeutic LMWH versus placebo, Outcome 1 Venous thromboembolism end-of- treatment.................................... 59 Analysis 3.2. Comparison 3 Therapeutic LMWH versus placebo, Outcome 2 Venous thromboembolism 3-month follow up. ..................................... 60 Analysis 3.3. Comparison 3 Therapeutic LMWH versus placebo, Outcome 3 Extension and/or recurrence of ST. 60 Analysis 3.4. Comparison 3 Therapeutic LMWH versus placebo, Outcome 4 Major bleeding. 61 Analysis 3.5. Comparison 3 Therapeutic LMWH versus placebo, Outcome 5 Heparin-induced thrombocytopenia. 61 Analysis 4.1. Comparison 4 Prophylactic LMWH + elastic compression stockings (ECS) versus elastic stockings alone, Outcome 1 Venous thromboembolism. 62 Analysis 4.2. Comparison 4 Prophylactic LMWH + elastic compression stockings (ECS) versus elastic stockings alone, Outcome 2 Extension and/or recurrence of ST. ...... 62 Analysis 5.1. Comparison 5 LMWH versus heparin spray gel, Outcome 1 Deep-venous thrombosis. 63 Analysis 5.2. Comparison 5 LMWH versus heparin spray gel, Outcome 2 Patients with thrombus at 21 days. 63 Analysis 5.3. Comparison 5 LMWH versus heparin spray gel, Outcome 3 Allergic reaction or elevated sedimentation rate...................................... 64 Analysis 6.1. Comparison 6 Therapeutic LMWH versus saphenofemoral disconnection, Outcome 1 Venous thromboembolism.. 64 Treatment for superficial thrombophlebitis of the leg (Review) i Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Analysis 6.2. Comparison 6 Therapeutic LMWH versus saphenofemoral disconnection, Outcome 2 Extension and/or recurrenceofST.................................. 65 Analysis 6.3. Comparison 6 Therapeutic LMWH versus saphenofemoral disconnection, Outcome 3 Major bleeding. 65 Analysis 6.4. Comparison 6 Therapeutic LMWH versus saphenofemoral disconnection, Outcome 4 Complications. 66 Analysis 7.1. Comparison 7 Fixed-dose LMWH versus NSAIDs, Outcome 1 Venous thromboembolism. 66 Analysis 7.2. Comparison 7 Fixed-dose LMWH versus NSAIDs, Outcome 2 Extension and/or treatment of ST. 67 Analysis 7.3. Comparison 7 Fixed-dose LMWH versus NSAIDs, Outcome 3 Major bleeding. 67 Analysis 7.4. Comparison 7 Fixed-dose LMWH versus NSAIDs, Outcome 4 Heparin-induced thrombocytopenia. 68 Analysis 8.1. Comparison 8 Weight-adjusted LMWH versus NSAIDs, Outcome 1 Venous thromboembolism. 68 Analysis 8.2. Comparison 8 Weight-adjusted LMWH versus NSAIDs, Outcome 2 Extension and/or recurrence of ST. 69 Analysis 8.3. Comparison 8 Weight-adjusted LMWH versus NSAIDs, Outcome 3 Major bleeding. 69 Analysis 8.4. Comparison 8 Weight-adjusted LMWH versus NSAIDs, Outcome 4 Heparin-induced thrombocytopenia. 70 Analysis 9.1. Comparison 9 Prophylactic LMWH versus NSAIDs, Outcome 1 Venous thromboembolism end-of- treatment.................................... 70 Analysis 9.2. Comparison 9 Prophylactic LMWH versus NSAIDs, Outcome 2 Venous thromboembolism 3-month follow up. ..................................... 71 Analysis 9.3. Comparison 9 Prophylactic LMWH versus NSAIDs, Outcome 3 Major bleeding. 71 Analysis 9.4. Comparison 9 Prophylactic LMWH versus NSAIDs, Outcome 4 Heparin-induced thrombocytopenia. 72 Analysis 10.1. Comparison 10 LMWH versus LMWH + acemetacin, Outcome 1 Pulmonary embolism. 72 Analysis 10.2. Comparison 10 LMWH versus LMWH + acemetacin, Outcome 2 Deep vein thrombosis. 73 Analysis 10.3. Comparison 10 LMWH versus LMWH + acemetacin, Outcome 3 Extension of ST. 73 Analysis 10.4. Comparison 10 LMWH versus LMWH + acemetacin, Outcome 4 Pain reduction. 74 Analysis 10.5. Comparison 10 LMWH versus LMWH + acemetacin, Outcome 5 Hyperaemia reduction. 74 Analysis 10.6. Comparison 10 LMWH versus LMWH + acemetacin, Outcome 6 Tenderness reduction. 75 Analysis 10.7. Comparison 10 LMWH versus LMWH + acemetacin, Outcome 7 Palpable cord reduction. 75 Analysis 10.8. Comparison 10 LMWH versus LMWH + acemetacin, Outcome 8 Mortality. 76 Analysis 10.9. Comparison 10 LMWH versus LMWH + acemetacin, Outcome 9 Major bleeding. 76 Analysis 10.10. Comparison 10 LMWH versus LMWH + acemetacin, Outcome 10 Minor bleeding. 77 Analysis 10.11. Comparison 10 LMWH versus LMWH + acemetacin, Outcome 11 Adverse event. 77 Analysis 11.1. Comparison 11 Fixed-dose LMWH versus weight-adjusted LMWH, Outcome 1 ST or venous thromboembolism.. 78 Analysis 11.2. Comparison 11 Fixed-dose LMWH versus weight-adjusted LMWH, Outcome 2 Venous thromboembolism.. 78 Analysis 11.3. Comparison 11 Fixed-dose LMWH versus weight-adjusted LMWH, Outcome 3 Superficial thrombophlebitis. 79 Analysis 11.4. Comparison 11 Fixed-dose LMWH versus weight-adjusted LMWH, Outcome 4 Swelling disappearance. 79 Analysis 11.5. Comparison 11 Fixed-dose LMWH versus weight-adjusted LMWH, Outcome 5 Tenderness disappearance. 80 Analysis 11.6. Comparison 11 Fixed-dose LMWH versus weight-adjusted LMWH, Outcome 6 Pain disappearance. 80 Analysis 11.7. Comparison 11 Fixed-dose LMWH versus weight-adjusted LMWH, Outcome 7 Pitting oedema disappearance. ................................. 81 Analysis 11.8. Comparison 11 Fixed-dose LMWH versus weight-adjusted LMWH, Outcome 8 Collateral veins disappearance. ................................. 81 Analysis 11.9. Comparison 11 Fixed-dose LMWH versus weight-adjusted LMWH, Outcome 9 Redness disappearance. 82 Analysis 11.10. Comparison 11 Fixed-dose LMWH versus weight-adjusted LMWH, Outcome 10 Palpable cord disappearance. ................................. 82 Analysis 11.11. Comparison 11 Fixed-dose LMWH versus weight-adjusted LMWH, Outcome 11 Major bleeding. 83 Analysis 11.12. Comparison 11 Fixed-dose LMWH versus weight-adjusted LMWH, Outcome 12 Heparin-induced thrombocytopenia. 83 Analysis 12.1. Comparison 12 Prophylactic UFH + elastic compression stockings versus elastic compression stockings alone, Outcome 1 Venous thromboembolism. ....... 84 Analysis 12.2. Comparison 12 Prophylactic UFH + elastic compression stockings versus elastic compression stockings alone, Outcome 2 Extension and/or recurrence of ST. .......... 84 Analysis 13.1. Comparison 13 High-dose UFH versus low-dose UFH, Outcome 1 Incidence of venous thromboembolism. 85 Treatment for superficial thrombophlebitis of the leg (Review) ii Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Analysis 13.2. Comparison 13 High-dose UFH versus low-dose UFH, Outcome 2 ST recurrence or extension. 85 Analysis 13.3. Comparison 13 High-dose UFH versus low-dose UFH, Outcome 3 Major bleeding. 86 Analysis 13.4. Comparison 13 High-dose UFH versus low-dose UFH, Outcome 4 Heparin-induced thrombocytopenia. 86 Analysis 14.1. Comparison 14 Calcium heparin + elastic compression bandage versus elastic compression bandage alone, Outcome 1 Deep venous thrombosis. 87 Analysis 15.1.
Load more

Recommended publications
  • Clinical Case: Post-Procedure Thrombophlebitis
    Clinical Case: Post-procedure Thrombophlebitis A 46 year old female presented with long-standing history of right lower limb fatigue and aching with prolonged standing. Symptoms –Aching, cramping, heavy, tired right lower limb –Tenderness over bulging veins –Symptoms get worse at end of the day –She feels better with lower limb elevation and application of elastic compression stockings (ECS) History Medical and Surgical history: Sjogren syndrome, mixed connective tissue disease, GERD, IBS G2P2 with C-section x2, left breast biopsy No history of venous thrombosis Social history: non-smoker Family history: HTN, CAD Allergies: None Current medications: Pantoprazole Physical exam Both lower limbs were warm and well perfused Palpable distal pulses Motor and sensory were intact Prominent varicosities Right proximal posterior-lateral thigh and medial thigh No ulcers No edema Duplex ultrasound right lower limb GSV diameter was 6.4mm and had reflux from the SFJ to the distal thigh No deep venous reflux No deep vein thrombosis Duplex ultrasound right lower limb GSV tributary diameter 4.6mm Anterior thigh varicose veins diameter 1.5mm-2.6mm with reflux No superficial vein thrombosis What is the next step? –Conservative treatment – Phlebectomies –Sclerotherapy –Thermal ablation –Thermal ablation, phlebectomies and sclerotherapy Treatment Right GSV radiofrequency ablation Right leg ultrasound guided foam sclerotherapy with 0.5% sodium tetradecyl sulfate (STS) Right leg ambulatory phlebectomies x19 A compression dressing and ECS were applied to the right lower limb after the procedure. Follow-up 1 week post-procedure –The right limb was warm and well perfused –There was mild bruising, no infection and signs of mild thrombophlebitis –Right limb venous duplex revealed no deep vein thrombosis and the GSV was occluded 2 weeks post-procedure –Tender palpable cord was found in the right thigh extending into the calf with overlying hyperpigmentation.
    [Show full text]
  • Pulmonary Veno-Occlusive Disease
    Arch Dis Child: first published as 10.1136/adc.42.223.322 on 1 June 1967. Downloaded from Arch. Dis. Childh., 1967, 42, 322. Pulmonary Veno-occlusive Disease K. WEISSER, F. WYLER, and F. GLOOR From the Departments of Paediatrics and Pathology, University of Basle, Switzerland Pulmonary venous congestion with or without time. She gradually became more dyspnoeic, with 'reactive' or 'protective' pulmonary arterial hyper- increasing weakness and fatigue, and her weight fell. tension (Wood, 1954; Wood, Besterman, Towers, In October 1961 she developed jaundice with acholic and McIlroy, 1957) is most commonly caused by stools and dark urine. Infective hepatitis was diagnosed, and she was put on a diet and, 2 weeks later, on corti- left heart disease. The obstruction to blood flow costeroids. She had had no known contact with a case may, however, also be located upstream to the left of hepatitis. Again, except for her dyspnoea, no cardiac atrium. Among the known causes of such obstruc- or pulmonary abnormality was found. The icterus tion are compression of the pulmonary veins by a decreased very slowly, but never disappeared entirely. mediastinal mass (Edwards and Burchell, 1951; In the following months her general condition deteriora- Andrews, 1957; Evans, 1959); congenital stenosis of ted and she was breathless even at rest. On two occasions the pulmonary veins at the veno-atrial junction she had syncopal attacks lasting a few minutes. She lost (Lucas, Woolfrey, Anderson, Lester, and Edwards, 12 kg. within one year. In January 1962 the parents finally consented to her being admitted to hospital. 1962); or thrombus formation in the pulmonary On admission she was obviously ill, wasted, jaundiced, veins due to greatly reduced blood flow associated cyanotic, and severely dyspnoeic and orthopnoeic.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Characterising the Risk of Major Bleeding in Patients With
    EU PE&PV Research Network under the Framework Service Contract (nr. EMA/2015/27/PH) Study Protocol Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Version 3.0 1 June 2018 EU PAS Register No: 16014 EMA/2015/27/PH EUPAS16014 Version 3.0 1 June 2018 1 TABLE OF CONTENTS 1 Title ........................................................................................................................................... 5 2 Marketing authorization holder ................................................................................................. 5 3 Responsible parties ................................................................................................................... 5 4 Abstract ..................................................................................................................................... 6 5 Amendments and updates ......................................................................................................... 7 6 Milestones ................................................................................................................................. 8 7 Rationale and background ......................................................................................................... 9 8 Research question and objectives .............................................................................................. 9 9 Research methods ....................................................................................................................
    [Show full text]
  • Sulodexide: Review of Recent Clinical Efficacy Data
    ISSN 2277-0879; Volume 2, Issue 5, pp. 57-61; May, 2013 Online Journal of Medicine and Medical Science Research ©2013 Online Research Journals Review Article Available Online at http://www.onlineresearchjournals.org/JMMSR Sulodexide: Review of recent clinical efficacy data Massimo Milani MD Private practice, Milan Italy, Via A. Nota 18, Milan, Italy. E-Mail: [email protected]. Received 17 April, 2013 Accepted 8 May, 2013 Sulodexide (SLX) is a peculiar and interesting antithrombotic drug. It is a highly purified mixture of glycosaminoglycans (GAG) with anticoagulant and antithrombotic properties used for the prophylaxis and treatment of thromboembolic diseases. The pharmacological effects of SLX differ substantially from other GAG and are mainly characterized by a prolonged half-life and reduced effect on global coagulation and bleeding parameters. SLX is able to potentiate the antiprotease activities of both antithrombin III and heparin cofactor II. SLX shows also in vitro and in vivo profibrinolytic actions. SLX exhibits antithrombotic and profibrinolytic properties in several animal models of venous and arterial thrombosis and has relatively high affinity for endothelial cells. By oral route SLX is able to release tissue plasminogen activator and increase fibrinolytic activities. SLX is clinically effective in the treatment of peripheral arterial vascular diseases and in the treatment of deep venous thrombosis. SLX has also been found clinically active in the treatment of venous ulcers of the leg. SLX has been also used with success in tinnitus and in the thrombosis of central ocular vein. Recent data suggest that SLX could have beneficial effects in the treatment of diabetic nephropathy and in reducing microalbuminuria.
    [Show full text]
  • Inherited Thrombophilia Protein S Deficiency
    Inherited Thrombophilia Protein S Deficiency What is inherited thrombophilia? If other family members suffered blood clots, you are more likely to have inherited thrombophilia. “Inherited thrombophilia” is a condition that can cause The gene mutation can be passed on to your children. blood clots in veins. Inherited thrombophilia is a genetic condition you were born with. There are five common inherited thrombophilia types. How do I find out if I have an They are: inherited thrombophilia? • Factor V Leiden. Blood tests are performed to find inherited • Prothrombin gene mutation. thrombophilia. • Protein S deficiency. The blood tests can either: • Protein C deficiency. • Look at your genes (this is DNA testing). • Antithrombin deficiency. • Measure protein levels. About 35% of people with blood clots in veins have an inherited thrombophilia.1 Blood clots can be caused What is protein S deficiency? by many things, like being immobile. Genes make proteins in your body. The function of Not everyone with an inherited thrombophilia will protein S is to reduce blood clotting. People with get a blood clot. the protein S deficiency gene mutation do not make enough protein S. This results in excessive clotting. How did I get an inherited Sometimes people produce enough protein S but the thrombophilia? mutation they have results in protein S that does not Inherited thrombophilia is a gene mutation you were work properly. born with. The gene mutation affects coagulation, or Inherited protein S deficiency is different from low blood clotting. The gene mutation can come from one protein S levels seen during pregnancy. Protein S levels or both of your parents.
    [Show full text]
  • CT Observations Pertinent to Septic Cavernous Sinus Thrombosis
    755 CT Observations Pertinent to Septic Cavernous Sinus Thrombosis Jamshid Ahmadi1 The use of high-resolution computed tomography (CT) is described in four patients James R. Keane2 with septic cavernous sinus thrombosis, In all patients CT findings included multiple Hervey D. Segall1 irregular filling defects in the enhancing cavernous sinus. Unilateral or bilateral inflam­ Chi-Shing Zee 1 matory changes in the orbital soft tissues were also present. Enlargement of the superior ophthalmic vein due to extension of thrombophlebitis was noted in three patients. Since the introduction of antibiotics, septic cavernous sinus thrombosis (throm­ bophlebitis) has become a rare disease [1-4]. Despite considerable improvement in morbidity and mortality (previously almost universal), it remains a potentially lethal disease. The diagnosis of cavernous sinus thrombophlebitis requires a careful clinical evaluation supplemented with appropriate laboratory and radiographic studies. Current computed tomographic (CT) scanners (having higher spatial and contrast resolution) play an important role in the radiographic evaluation of the diverse pathologiC processes that involve the cavernous sinus [5-7]. The use of CT has been documented in several isolated cases [8-13], and small series [14] dealing with the diagnosis and management of cavernous sinus thrombophlebitis. CT scanning in these cases was reported to be normal in two instances [8 , 10]. In other cases so studied, CT showed abnormalities such as orbital changes [11 , 14], paranasal sinusitis [12], and associated manifestations of intracranial infection [9]; however, no mention was made in these cases of thrombosis within the cavernous sinus itself. Direct CT demonstration of thrombosis within the cavernous sinus has been rarely reported [13].
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia
    A publication of the PHARMACEUTICAL SERVICES DIVISION AND THE CLINICAL RESEARCH CENTRE MINISTRY OF HEALTH MALAYSIA MALAYSIAN STATISTICS ON MEDICINES 2008 Edited by: Lian L.M., Kamarudin A., Siti Fauziah A., Nik Nor Aklima N.O., Norazida A.R. With contributions from: Hafizh A.A., Lim J.Y., Hoo L.P., Faridah Aryani M.Y., Sheamini S., Rosliza L., Fatimah A.R., Nour Hanah O., Rosaida M.S., Muhammad Radzi A.H., Raman M., Tee H.P., Ooi B.P., Shamsiah S., Tan H.P.M., Jayaram M., Masni M., Sri Wahyu T., Muhammad Yazid J., Norafidah I., Nurkhodrulnada M.L., Letchumanan G.R.R., Mastura I., Yong S.L., Mohamed Noor R., Daphne G., Kamarudin A., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Omar I., Zoriah A., Fong Y.Y.A., Nusaibah A.R., Feisul Idzwan M., Ghazali A.K., Hooi L.S., Khoo E.M., Sunita B., Nurul Suhaida B.,Wan Azman W.A., Liew H.B., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Asmah J., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I., Ghazali I., Wan Abu Bakar Y., Wan Hamilton W.H., Ravichandran J., Zaridah S., Wan Zahanim W.Y., Kannappan P., Intan Shafina S., Tan A.L., Rohan Malek J., Selvalingam S., Lei C.M.C., Ching S.L., Zanariah H., Lim P.C., Hong Y.H.J., Tan T.B.A., Sim L.H.B, Long K.N., Sameerah S.A.R., Lai M.L.J., Rahela A.K., Azura D., Ibtisam M.N., Voon F.K., Nor Saleha I.T., Tajunisah M.E., Wan Nazuha W.R., Wong H.S., Rosnawati Y., Ong S.G., Syazzana D., Puteri Juanita Z., Mohd.
    [Show full text]
  • Varicose Veins and Superficial Thrombophlebitis
    ENTITLEMENT ELIGIBILITY GUIDELINES VARICOSE VEINS AND SUPERFICIAL THROMBOPHLEBITIS 1. VARICOSE VEINS MPC 00727 ICD-9 454 DEFINITION Varicose Veins of the lower extremities are a dilatation, lengthening and tortuosity of a subcutaneous superficial vein or veins of the lower extremity such as the saphenous veins and perforating veins. A diagnosis of varicose veins is sometimes made in error when the veins are prominent but neither varicose or abnormal. This guideline excludes Deep Vein Thrombosis, and telangiectasis. DIAGNOSTIC STANDARD Diagnosis by a qualified medical practitioner is required. ANATOMY AND PHYSIOLOGY The venous system of the lower extremities consists of: 1. The deep system of veins. 2. The superficial veins’ system. 3. The communicating (or perforating) veins which connect the first two systems. There are primary and secondary causes of varicose veins. Primary causes are congenital and/or may develop from inherited conditions. Secondary causes generally result from factors other than congenital factors. VETERANS AFFAIRS CANADA FEBRUARY 2005 Entitlement Eligibility Guidelines - VARICOSE VEINS/SUPERFICIAL THROMBOPHLEBITIS Page 2 CLINICAL FEATURES Clinical onset usually takes place when varicosities in the affected leg or legs appear. Varicosities typically present as a bluish discolouration and may have a raised appearance. The affected limb may also demonstrate the following: • Aching • Discolouration • Inflammation • Swelling • Heaviness • Cramps Varicose Veins may be large and apparent or quite small and barely discernible. Aggravation for the purposes of Varicose Veins may be represented by the veins permanently becoming larger or more extensive, or a need for operative intervention, or the development of Superficial Thrombophlebitis. PENSION CONSIDERATIONS A. CAUSES AND/OR AGGRAVATION THE TIMELINES CITED BELOW ARE NOT BINDING.
    [Show full text]
  • Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
    How can it be prevented? You can take steps to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). If you're at risk for these conditions: • See your doctor for regular checkups. • Take all medicines as your doctor prescribes. • Get out of bed and move around as soon as possible after surgery or illness (as your doctor recommends). Moving around lowers your chance of developing a blood clot. References: • Exercise your lower leg muscles during Deep Vein Thrombosis: MedlinePlus. (n.d.). long trips. Walking helps prevent blood Retrieved October 18, 2016, from clots from forming. https://medlineplus.gov/deepveinthrombos is.html If you've had DVT or PE before, you can help prevent future blood clots. Follow the steps What Are the Signs and Symptoms of Deep above and: Vein Thrombosis? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from • Take all medicines that your doctor http://www.nhlbi.nih.gov/health/health- prescribes to prevent or treat blood clots topics/topics/dvt/signs • Follow up with your doctor for tests and treatment Who Is at Risk for Deep Vein Thrombosis? - • Use compression stockings as your DEEP NHLBI, NIH. (n.d.). Retrieved October 18, doctor directs to prevent leg swelling 2016, from http://www.nhlbi.nih.gov/health/health- VEIN topics/topics/dvt/atrisk THROMBOSIS How Can Deep Vein Thrombosis Be Prevented? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from (DVT) http://www.nhlbi.nih.gov/health/health- topics/topics/dvt/prevention How Is Deep Vein Thrombosis Treated? - NHLBI, NIH. (n.d.). Retrieved October 18, 2016, from http://www.nhlbi.nih.gov/health/health- topics/topics/dvt/treatment Trinity Surgery Center What is deep vein Who is at risk? What are the thrombosis (DVT)? The risk factors for deep vein thrombosis symptoms? (DVT) include: Only about half of the people who have DVT A blood clot that forms in a vein deep in the • A history of DVT.
    [Show full text]
  • Successful Surgical Management of Mesenteric Inflammatory Veno
    Matsuda et al. Surgical Case Reports (2020) 6:27 https://doi.org/10.1186/s40792-020-0796-1 CASE REPORT Open Access Successful surgical management of mesenteric inflammatory veno-occlusive disease Keiji Matsuda1* , Yojiro Hashiguchi1, Yoshinao Kikuchi2, Kentaro Asako1, Kohei Ohno1, Yuka Okada1, Takahiro Yagi1, Mitsuo Tsukamoto1, Yoshihisa Fukushima1, Ryu Shimada1, Tsuyoshi Ozawa1, Tamuro Hayama1, Takeshi Tsuchiya1, Keijiro Nozawa1, Yuko Sasajima2 and Fukuo Kondo2 Abstract Background: The term “mesenteric inflammatory veno-occlusive disease (MIVOD)” is used to describe an ischemic injury resulting from phlebitis or venulitis that affects the bowel or mesentery in the absence of arteritis. MIVOD is difficult to diagnose because of its rarity and frequent confusion with other diseases. The incidence and etiology of MIVOD remain unclear; only a few cases have been reported. We describe a case of the successful surgical management of a patient with MIVOD with characteristic images. Case presentation: A 65-year-old Japanese man visited a hospital with the chief complaint of abdominal pain in January 2018. CT showed edema and thickening of the intestinal wall from the descending colon to the rectum. The patient was admitted to the hospital. Suspected diagnoses were enteritis, ulcerative colitis, amyloidosis, vasculitis, malignant lymphoma, and venous thrombus, but no definitive diagnosis was obtained. The patient was transferred to our hospital for the treatment of stenosis (located from the descending colon to the rectum) and bowel obstruction. An emergency transverse colostomy was performed. The sigmoid colon and mesentery were too rigid and edematous to resect. Colonic hemorrhage occurred 2 weeks after the surgery. With radiology intervention, coiling for the arteriovenous fistula in the descending colon was performed, and hemostasis was obtained.
    [Show full text]